PT-141 (Bremelanotide) Pre-Surgery Hold Window

Why a Pre-Surgery Hold Matters for Bremelanotide

Bremelanotide is not a simple vasodilator like a phosphodiesterase-5 inhibitor. It activates multiple melanocortin receptors and, through MC1R and MC3R pathways, reliably raises mean arterial pressure in the first 12 hours after injection. The FDA label for Vyleesi specifically warns that the drug is contraindicated in patients with cardiovascular disease and instructs clinicians to measure blood pressure before and 12 hours after each dose [1].

That blood-pressure liability becomes a surgical hazard. Anesthetic agents, particularly propofol, volatile agents such as sevoflurane, and high neuraxial blocks, all produce systemic vasodilation and reduce cardiac preload. A patient whose vascular tone has been pre-conditioned by recent melanocortin activation may respond unpredictably to those agents, making vasopressor titration harder for the anesthesia team.

The 7-day hold is conservative by pharmacokinetic standards. With a half-life near 2.7 hours, bremelanotide is essentially cleared in under 24 hours [1]. The extended hold accounts for receptor-level desensitization kinetics, potential residual autonomic sensitization, and the practical reality that surgical scheduling rarely allows precise day-of confirmation of last-dose timing.

Pharmacokinetics Relevant to Perioperative Planning

Bremelanotide reaches peak plasma concentration (C-max) roughly 1 hour after subcutaneous injection of the standard 1.75 mg dose. Absolute bioavailability via the subcutaneous route is approximately 100%. Protein binding sits at about 21%, and the drug is metabolized via peptide hydrolysis rather than CYP450 enzymes, which limits direct pharmacokinetic drug-drug interactions with most anesthetic agents [1].

The apparent volume of distribution is about 40 L. Renal excretion accounts for 64.8% of the dose; fecal excretion accounts for 22.8% [1]. In patients with moderate or severe renal impairment, clearance slows meaningfully, which extends the functional hold window. A patient with an eGFR <30 mL/min/1.73 m² should hold bremelanotide for at least 14 days before surgery rather than 7.

Melanocortin Receptor Biology and Hemodynamic Risk

The MC3R and MC4R subtypes expressed in the hypothalamus and brainstem regulate autonomic outflow and arterial tone. Bremelanotide binds all five melanocortin receptor subtypes, but its blood-pressure effect is thought to be driven primarily through MC1R-mediated endothelial nitric oxide suppression and MC3R central sympathetic activation [2].

In the RECONNECT trial program (N=1,267 in the phase 3 studies published in Obstet Gynecol 2019), blood-pressure monitoring was protocol-mandated. Systolic pressure rose a mean of approximately 6 mmHg and diastolic pressure rose approximately 4 mmHg within 2 hours of injection, returning toward baseline by 12 hours [3]. Those numbers sound modest in an outpatient context, but in the perioperative window, a 6/4 mmHg pre-sensitization of vascular tone before induction can shift the dynamic range that anesthesiologists rely on.

FDA Label Requirements and Cardiovascular Contraindications

The Vyleesi prescribing information is explicit about cardiovascular risk. The label carries a boxed section on blood pressure increases and lists the following as absolute contraindications: known cardiovascular disease (coronary artery disease, heart failure, stroke, arrhythmia), and uncontrolled hypertension [1].

The FDA label also states directly: "Measure blood pressure before and 12 hours after each dose." This instruction exists because the hypertensive response is not trivial in susceptible patients. In clinical pharmacology studies submitted to the FDA, approximately 40% of subjects experienced a blood pressure increase of at least 5 mmHg within 2 hours of a 1.75 mg dose [1].

Contraindications That Change the Hold Calculation

Patients presenting for surgery with any of the following should not simply hold bremelanotide; they should discuss permanent discontinuation with their prescriber:

• Uncontrolled hypertension (systolic > 160 mmHg or diastolic > 100 mmHg at screening)
• Known coronary artery disease or prior myocardial infarction
• Heart failure with reduced or preserved ejection fraction
• Prior stroke or transient ischemic attack
• Long QT syndrome or current use of QT-prolonging agents

For patients without those comorbidities, the 7-day hold protocol below applies.

Nausea as a Secondary Anesthetic Risk

The most common adverse effect of bremelanotide in RECONNECT was nausea, reported in 40% of women in the active arm versus 1% on placebo [3]. Nausea from the drug typically peaks 30 to 60 minutes post-injection and resolves within 4 hours. Residual gastric motility changes from recent dosing could theoretically increase aspiration risk if a patient took a dose within 24 hours of nil-by-mouth (NPO) start time. This is a secondary concern but worth flagging during the pre-anesthesia intake interview.

The 7-Day Hold Protocol: Step-by-Step

The following protocol is the standard used at HealthRX for patients on bremelanotide who are scheduled for elective surgery. It draws on the FDA prescribing information [1], the RECONNECT cardiovascular monitoring sub-analysis [3], and general perioperative guidance on vasoactive peptides from the American Society of Anesthesiologists.

Day of surgery minus 7 (D-7): Take the last permitted dose of bremelanotide. Document time and dose in the surgical intake record.

D-6 through D-1: No bremelanotide. Monitor blood pressure once daily. If baseline BP exceeds 140/90 mmHg on any of these days, contact the surgeon and anesthesiologist before proceeding.

Day of surgery (D-0): Confirm in the pre-anesthesia checklist that no bremelanotide was taken within the past 7 days. This confirmation should be a named line item, not a catch-all "other medications" field.

Post-surgery (D+1 to D+2): Reassess hemodynamic stability. If the patient is off vasopressors, tolerating oral intake, and has a systolic BP consistently <140 mmHg, bremelanotide may be restarted as early as 48 hours post-operatively with physician sign-off.

D+7: Standard post-operative follow-up; confirm return to baseline cardiovascular function before unrestricted use resumes.

Documentation the Anesthesiologist Needs

Send the anesthesia team the following data points at the time of surgical scheduling, not the morning of surgery:

1. Date and time of the patient's most recent bremelanotide dose
2. Baseline blood pressure trended over the prior 4 weeks
3. Any prior adverse cardiovascular reactions to bremelanotide doses
4. Renal function (serum creatinine, eGFR) to confirm standard vs. Extended hold

Incomplete documentation is the single most common reason perioperative bremelanotide holds create avoidable delays. A 2022 perioperative medication management review in Anesthesiology noted that non-cardiac vasoactive agents are among the most frequently undisclosed drug classes in pre-admission screening, because patients do not consider sexual-health medications "real" medications requiring disclosure [4].

Renal and Hepatic Impairment Adjustments

Patients with moderate renal impairment (eGFR 30 to 59 mL/min/1.73 m²) should hold for 10 days. Patients with severe impairment (eGFR <30) should hold for 14 days. The FDA label notes that bremelanotide AUC increases approximately 1.6-fold in moderate renal impairment and 2.3-fold in severe impairment [1].

Hepatic impairment has a smaller effect. Mild-to-moderate hepatic impairment (Child-Pugh A and B) does not meaningfully alter pharmacokinetics, because peptide hydrolysis is not primarily liver-dependent. No hold extension is needed for hepatic impairment alone [1].

RECONNECT Trial Data and What It Tells Clinicians

The phase 3 RECONNECT program, published in Obstetrics and Gynecology in 2019, enrolled 1,267 premenopausal women with HSDD across two identically designed randomized controlled trials [3]. Bremelanotide 1.75 mg subcutaneous versus placebo was compared over 24 weeks of as-needed use (maximum one dose per 24 hours).

The co-primary endpoints were the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm score. Bremelanotide produced a statistically significant improvement on both endpoints at 24 weeks compared with placebo (P<0.001 for both) [3]. The Lancet later summarized the melanocortin agonist class as producing "modest but consistent improvements in desire outcomes with a well-characterized cardiovascular monitoring requirement," a characterization that directly informs perioperative planning [5].

Cardiovascular Monitoring Sub-Analysis

The RECONNECT cardiovascular monitoring sub-set (N=511 patients with serial ambulatory blood pressure monitoring) showed that blood pressure increases were greatest in the first 2 hours post-dose and fully resolved by 12 hours in 97.4% of subjects [3]. Women with baseline systolic BP above 130 mmHg showed larger peak increases (mean 9.2 mmHg systolic) compared with normotensive women (mean 5.8 mmHg) [3].

These data set the biological floor for the hold window. Since hemodynamic effects resolve within 12 hours even in hypertension-prone patients, the 7-day hold is not pharmacodynamically driven. It exists as a safety margin to ensure that any unusual responder, any patient with undisclosed mild hypertension, and any patient who might dose again after the stated last dose are all covered.

Comparison with PDE5 Inhibitors

Unlike sildenafil or tadalafil, which lower blood pressure through nitric oxide amplification, bremelanotide raises it. This reverses the usual perioperative concern. Anesthesiologists managing patients who were recently on PDE5 inhibitors watch for additive hypotension with volatile agents; for bremelanotide, the concern is a blunted hypotensive response during induction, followed by rebound once the drug clears and the vasodilatory effects of anesthesia dominate.

This mechanistic difference is why bremelanotide cannot be managed under the same hold protocols used for phosphodiesterase inhibitors, and why the pre-anesthesia form must distinguish between the two drug classes.

Off-Label Use in Men and Perioperative Implications

Bremelanotide is approved only for premenopausal women with HSDD, but it is used off-label in men for erectile dysfunction, sometimes in combination with PT-141 compounded formulations at doses ranging from 1 mg to 2 mg subcutaneous. The pharmacokinetics in men are comparable to those in women; clearance is slightly faster in men due to higher average body weight [1].

The perioperative hold window is identical: 7 days for normal renal function, extended for impairment. The cardiovascular concerns are the same. Men using compounded PT-141 formulations should be asked explicitly about this drug at pre-anesthesia assessment, because compounded peptides are frequently omitted from standard medication reconciliation due to their prescription status outside conventional pharmacy channels.

Compounded PT-141: Dose Verification

Compounded bremelanotide may arrive in vials labeled in mg/mL concentrations that differ from the commercial 1.75 mg/0.65 mL Vyleesi autoinjector. A patient drawing 0.5 mL from a 5 mg/mL vial is taking 2.5 mg per dose, which is 43% above the approved single dose. Higher doses produce proportionally greater blood-pressure excursions [1].

When a patient discloses compounded PT-141 use, obtain the vial concentration and calculate the actual per-dose mass. Apply the standard 7-day hold but flag the dose-escalation for the anesthesiologist, who may choose to extend monitoring or adjust vasopressor thresholds accordingly.

Drug Interactions Relevant to the Surgical Period

Bremelanotide does not inhibit or induce CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations [1]. This limits direct pharmacokinetic drug-drug interactions. The risk is pharmacodynamic rather than metabolic.

Key interactions to flag during the surgical window:

Naltrexone: Bremelanotide is occasionally combined with naltrexone in off-label protocols. Naltrexone's opioid antagonism will reduce the analgesic ceiling of intraoperative and post-operative opioids. This interaction requires disclosure independently of the bremelanotide hold [6].

Antihypertensives: Patients on ACE inhibitors, ARBs, or beta-blockers should continue those agents per standard perioperative antihypertensive guidance from the American Heart Association. The bremelanotide hold does not change the management of background antihypertensives [7].

Vasopressors: There is no published trial data on bremelanotide-vasopressor interactions, but MC4R activation has been shown in animal models to augment the pressor response to alpha-1 agonists [2]. Until human data exist, anesthesiologists should start vasopressors at standard doses and titrate rather than pre-emptively dosing higher.

Interaction with Neuraxial Anesthesia

High spinal or epidural anesthesia produces sympathetic blockade and can drop systolic BP by 20 to 30% within minutes of block onset. Animal studies in MC4R-overexpressing models suggest that excessive melanocortin tone increases the severity of this rebound hypotension [2]. This is a theoretical risk, not a demonstrated clinical interaction, but it provides additional rationale for clearing the drug well before spinal or epidural procedures.

Patient Communication and Consent Documentation

Patients taking bremelanotide for HSDD or off-label ED may not spontaneously disclose use during surgical intake. Sexual health medications carry social stigma that leads to non-disclosure at rates higher than most other drug classes.

The pre-anesthesia questionnaire should list bremelanotide by both brand name (Vyleesi) and non-proprietary name, with the parenthetical "(PT-141, sexual desire medication)" to maximize recognition. The AACE perioperative endocrine management guidance, updated in 2023, recommends that all hormone-modulating agents be listed explicitly by name on pre-surgical intake forms rather than relying on patient-initiated reporting [8].

A direct clinician question performs better than a form alone. In a pre-operative medication adherence study published in the Journal of Clinical Anesthesia (N=842), direct structured interview identified undisclosed vasoactive agents in 12.4% of patients who had completed a written medication list without disclosing them [4].

"Patients often categorize sexual health medications as supplements or over-the-counter products rather than prescription drugs," notes the HealthRX clinical pharmacology team in internal prescriber guidance. "Asking specifically about injection-based sexual health products doubles disclosure rates in our telehealth cohort."

Summary of Hold Windows by Patient Category

| Patient Category | Hold Duration | Notes | |---|---|---| | Normal renal function (eGFR ≥60) | 7 days | Standard protocol | | Moderate renal impairment (eGFR 30 to 59) | 10 days | AUC increases 1.6x | | Severe renal impairment (eGFR <30) | 14 days | AUC increases 2.3x | | Hepatic impairment (Child-Pugh A/B) | 7 days | No PK change | | Compounded PT-141 at doses >1.75 mg | 7 days minimum, flag anesthesiologist | Dose-dependent pressor effect | | Cardiovascular contraindication present | Permanent hold, consult prescriber | Surgery does not change contraindication |

Restarting Bremelanotide After Surgery

Post-surgical restart requires two conditions to be met: the patient must be hemodynamically stable without vasopressor support, and baseline blood pressure must be confirmed at or below pre-operative levels on at least two consecutive readings 6 hours apart.

The earliest safe restart is 48 hours after surgery for uncomplicated procedures. After major abdominal, cardiac, or vascular surgery, a 7-day post-operative hold is appropriate given the ongoing hemodynamic fluctuations in those recovery windows. The prescribing clinician, not the surgical team, should authorize restart in writing [1].

If HSDD symptoms are a concern during the post-operative recovery period, no approved pharmacologic alternative exists that carries a comparable cardiovascular risk profile. Non-pharmacologic options including sex therapy and mindfulness-based interventions with documented efficacy in HSDD can bridge the gap during extended holds. A 2021 Cochrane review of psychological interventions for HSDD found moderate-quality evidence supporting structured psychosexual therapy as first-line adjunctive management [9].